Formycon And Bioeq Offer Ranibizumab Update
Partners Set Out Next Steps For Lucentis Biosimilar In US And EU
Formycon and partner Bioeq have offered further details on timing for the submission of their FYB201 proposed ranibizumab biosimilar version of Lucentis in Europe, the US and elsewhere.
